MiMARK and the EIC Accelerator: Diagnosing Endometrial Cancer

MiMARK Diagnostics, a spin-off of the Vall d'Hebron Research Institute based in the Barcelona Science Park, develops a laboratory test that measures five protein biomarkers in the fluid collected during a standard endometrial biopsy, so that endometrial cancer can be diagnosed even when the biopsy contains too few cells. About 31% of women who undergo such a biopsy get no final diagnosis for that reason and are sent for more invasive procedures, the company says. It was selected in the EIC Accelerator's March 2023 cut-off and received an EU grant of €2.50 million for WomEC, a €3.85 million project that ran from October 2023 to June 2026, according to CORDIS. The objective said clinical validation and commercialisation were "expected for 2024".

The only public report, to September 2024, lists patent work, preparation for ISO 13485 certification, regulatory pathway analysis for the EU and US, health-economic models and progress on the immunoassay, according to the CORDIS reporting page. The project targeted 99% sensitivity and a 97% negative predictive value. Its prospective study enrolled 1,950 patients from October 2023 and was completed in July 2025, according to ClinicalTrials.gov, where no results have been posted.

Where MiMARK Stands Now

MiMARK now presents its technology as the GyLDA platform, with an endometrial cancer test called GyLDEC and a second test, GyLDEndo, on its website. In April 2026 Catalan newspaper El Punt Avui reported that "Mimark cerca vuit milions per endinsar-se al mercat", that it is seeking €8 million to enter the market, according to the company's news page. Earlier it closed a €4.22 million seed round, according to Vall d'Hebron. The company reports annual revenue under €500,000, according to Empresia, and lists several Spanish and European public grants on its funding page.

The Technology: Reading Proteins, Not Cells

Endometrial cancer is diagnosed by examining cells from a biopsy under the microscope. When the sample is too small, women go on to hysteroscopy or other invasive tests. MiMARK instead measures proteins in the liquid part of the same sample with an antibody-based assay and a proprietary algorithm, so no extra procedure is needed. Its biomarkers were first tested in 530 patients in retrospective studies.

What the EIC Award Promised, and What the Record Shows

The award aimed to finish the assay, validate it clinically and bring it to market. A large prospective study was completed, which is real progress. But its accuracy has not been published, the test is not on sale, no IVDR certification has been announced, and the company says it needs another €8 million to launch.

1. Immunoassay developmentDeliveredPer first report.
2. Clinical validation studyDelivered1,950 patients, 2025.
3. Published accuracyUnverifiedNo results posted.
4. Market launchNot yetPlanned 2024.

The Money

The EU paid 65% of the project. MiMARK has been built on a series of public grants, from Spain and from EU programmes, plus a seed round. With revenue under €500,000 a year, it depends on the €8 million round it is raising to reach the market.

What Cannot Be Checked

Why Europe Should Care

Endometrial cancer is the most common gynaecological cancer in high-income countries, the report says, affecting close to 450,000 women a year worldwide. A test that avoids repeat invasive procedures would spare many women distress and cost health systems less. MiMARK has done the large study; publishing its results is the step that would let clinicians judge the test.

The Verdict

MiMARK Diagnostics and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.